GESSEL advises Bioceltix S.A. on transfer of its shares from NewConnect to the main floor of the Warsaw Stock Exchange

30.08.2022 News

GESSEL worked with Bioceltix S.A. on the prospect-less public offering, on preparations for floating of its shares on the Warsaw Stock Exchange regulated market, and on transfer of its shares from the NewConnect alternative trading system.

The prospectus concerning flotation of the shares on the Warsaw Stock Exchange was approved by the Polish Financial Supervision Authority on 28 July, and the first day of their listing has been set for 5 September.

GESSEL’s lawyers assisted with the requisite amendments of the corporate documentation, the actual public offering, and drafting of the prospectus as well as   representing the Company in proceedings before the Polish Financial Supervision Authority and the Warsaw Stock Exchange Board.

Our team, working under the supervision of Krzysztof Marczuk, partner, was composed of Jakub Rowicki, senior associate, Magdalena Szeplik, managing associate, Michał Dunikowski, associate and Piotr Blank, junior associate.

The Company also benefited from the advice of Dom Maklerski Navigator S.A. and CC Group sp. z o.o.

Bioceltix S.A. brings together a team of specialists developing innovative veterinary therapies harnessing the immunomodulation properties of stem cells, observing state-of-the-art quality and safety standards. Their research is conducted within the framework of an exacting business model.

You may also like

28.03.2024

Legal 500 international ranking just out, and GESSEL features prominently!

It’s awards season, and we at GESSEL are not done yet. The latest iteration of the Legal 500 ranking names our founding partner, Beata Gessel-Kalinowska vel Kalisz, as a...

News
Legal 500 international ranking just out, and GESSEL features prominently!

28.03.2024

Family foundation

LINK TO PDF

News
Family foundation
All posts

Do you want to be up to date?

Subscribe to the newsletter!